Parkinson's disease research advances with cell therapy trials and decision-aid studies

Recent developments in Parkinson's disease research highlight both advancements in cellular therapy and the need for improved decision-making tools for patients.

A Phase 3 clinical trial (BRT-DA01-301) is currently investigating the efficacy and safety of bemdaneprocel, a neuronal cell therapy, in adults with Parkinson's disease. This multicenter, randomized, double-blind study involves approximately 102 participants who will be compared against a sham surgery group. The study aims to evaluate how the therapy affects motor symptoms, quality of life, and disease severity over a follow-up period of up to five years.

Separately, research into deep brain stimulation (DBS) for Parkinson's disease has identified a potential gap in patient support. A study of United States-based neurology clinicians found that while healthcare providers recognize the potential benefits of patient decision aids (PtDAs) to help patients navigate the complexities of DBS, none of the interviewed clinicians had experience using such tools. Clinicians expressed optimism regarding the utility of these aids but noted a lack of consensus on the ideal format and implementation.